INTRODUCTION Mass vaccination against severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) offers the most efficient public health intervention to control the COVID-19 …

Neutralizing antibody responses gradually wane against several variants of concern (VOCs)
after vaccination with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …

Immune correlates of protection can be used as surrogate endpoints for vaccine efficacy.
The nonhuman primate (NHP) model of SARS-CoV-2 infection replicates key features of …

Omicron SARS-CoV-2 variants escape vaccine-induced neutralizing antibodies and cause
nearly all current COVID-19 cases. Here, we compared the efficacy of three booster …

An understanding of protective immunity to severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) is critical for vaccine and public health strategies aimed at ending the global …

Multiple preventive vaccines are being developed to counter the coronavirus disease 2019
pandemic. The leading candidates have now been evaluated in nonhuman primates (NHPs) …

Background Vaccines to prevent coronavirus disease 2019 (Covid-19) are urgently needed.
The effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines on …

Although mRNA vaccines encoding the spike protein of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) prevent COVID-19, the emergence of new viral variants …

Boosting immunity to COVID-19 vaccines | Nature Medicine Skip to main content Thank you for
visiting nature.com. You are using a browser version with limited support for CSS. To obtain the …

In the coronavirus efficacy (COVE) phase 3 clinical trial, vaccine recipients were assessed
for neutralizing and binding antibodies as correlates of risk for COVID-19 disease and as …